Related Case Studies
A First of its Kind Approval Changes the Way We Think About Access
A clinical-stage pharmaceutical company faced a unique barrier in bringing its first product to market—seeking pan-tumor approval based on a genetic marker, rather than a traditional approval based on cancer type. They subsequently sought recognition for the product across relevant clinical compendia.
View All Case Studies
- Healthcare policy changes interpreted in real-time
- A comprehensive launch strategy leads to broad access
- Understanding the European Market
- Insight into a new therapeutic landscape
- Strategizing a change in a company’s focus
- A novel therapy seeks to support physician reimbursement
- The Case is Made for New CPT Codes
- A Successful Transition from Europe to the US Market
- A First of its Kind Approval Changes the Way We Think About Access
